Acquisition Opportunity Prime Synthesis Inc was acquired by LGC Group, indicating a potential channel for integration opportunities, expanded distribution, and possible access to LGC’s customer base and resources for cross-selling CPG and oligonucleotide synthesis support products.

CPG Niche Focus As a leading producer of Controlled Pore Glass supports for oligonucleotide synthesis, PSI specializes in a high-value specialty material that complements suppliers, contract manufacturers, and biotech researchers seeking reliable synthesis substrates.

Small Biotech Profile With a lean team and modest revenue, PSI represents a target for scaled partnerships, licensing, or business development efforts that can leverage established niche capabilities without the overhead of a large organization.

Tech Stack Fit Current web and analytics stack (Drupal, jQuery, PHP, Google Analytics) suggests a mature digital presence with opportunities for enhanced marketing automation, CRM integration, and lifecycle campaigns to nurture prospects in biotech research.

Growth Readiness Post-acquisition expansion potential and alignment with LGC’s global footprint present opportunities for sales of related laboratory reagents, glassware, and instrument support services to broaden PSI’s product ecosystem.